Limits...
Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.

Fujita N, Tsujii S, Kuwata H, Kurokawa R, Matsunaga S, Okamura S, Mashitani T, Furuya M, Kitatani M, Ishii H - J Diabetes Investig (2012)

Bottom Line: The aim of the present study was to determine which characteristics of patients could influence the effectiveness of BOT introduction, and to obtain an equation to estimate HbA1c after BOT initiation.   Sixty consecutive insulin-naive type 2 diabetic patients with poor glycemic control (HbA1c ≥7.5%) started once-daily injections of insulin glargine.The best fitting multiple regression equation was: HbA1c at week 24 = 0.078 × duration of diabetes + 0.218 × HbA1c at baseline + 4.628 (r (2) = 0.437).   The equation based on the multiple linear regression models indicates necessary conditions for type 2 diabetic patients to achieve target HbA1c.The present findings emphasize the principle that early initiation of BOT in type 2 diabetes effectively achieves good glycemic control. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00164.x, 2011).

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology, Tenri Hospital, Nara, Japan.

ABSTRACT

Unlabelled: Aims/Introduction:  A method of estimating HbA1c attained after initiation of basal supported oral therapy (BOT) has not been reported previously. The aim of the present study was to determine which characteristics of patients could influence the effectiveness of BOT introduction, and to obtain an equation to estimate HbA1c after BOT initiation.

Materials and methods:   Sixty consecutive insulin-naive type 2 diabetic patients with poor glycemic control (HbA1c ≥7.5%) started once-daily injections of insulin glargine. Simple correlations were calculated between parameters such as HbA1c at baseline, HbA1c at week 24, reduction rate of HbA1c over 24 weeks (calculated as: [HbA1c level at baseline - HbA1c level at week 24]/HbA1c level at baseline), duration of diabetes, and the number of classes of coadministered oral antidiabetic drugs. Using multiple linear regression models, the independent effects of these parameters on HbA1c at week 24 were evaluated separately.

Results:   Multiple linear regression analysis revealed that duration of diabetes (β = 0.561; P < 0.001) and HbA1c at baseline (β = 0.284; P = 0.006) were significant predictors of HbA1c at week 24. The best fitting multiple regression equation was: HbA1c at week 24 = 0.078 × duration of diabetes + 0.218 × HbA1c at baseline + 4.628 (r (2) = 0.437).

Conclusions:   The equation based on the multiple linear regression models indicates necessary conditions for type 2 diabetic patients to achieve target HbA1c. The present findings emphasize the principle that early initiation of BOT in type 2 diabetes effectively achieves good glycemic control. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00164.x, 2011).

No MeSH data available.


Related in: MedlinePlus

 Duration of diabetes and HbA1c levels at baseline were significant determinants of the HbA1c level at 24 weeks. The HbA1c level to be attained at week 24 is calculated from the duration of diabetes and the HbA1c level at baseline.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4020734&req=5

f1:  Duration of diabetes and HbA1c levels at baseline were significant determinants of the HbA1c level at 24 weeks. The HbA1c level to be attained at week 24 is calculated from the duration of diabetes and the HbA1c level at baseline.

Mentions: Multiple linear regression analysis including HbA1c level at baseline, duration of diabetes, the number of classes of coadministered OADs, and HbA1c level at week 24 revealed that the duration of diabetes (β = 0.561; P < 0.001) and HbA1c level at baseline (β = 0.284; P = 0.006) were significant determinants of HbA1c level at 24 weeks (Figure 1). The best fitting multiple regression equation was: HbA1c level at week 24 = 0.078 × duration of diabetes + 0.218 × HbA1c level at baseline + 4.628 (r = 0.661; r2 = 0.437), on the conditions of diabetic duration in the range 1–35 years and HbA1c level in the range 7.5–14.5%.


Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.

Fujita N, Tsujii S, Kuwata H, Kurokawa R, Matsunaga S, Okamura S, Mashitani T, Furuya M, Kitatani M, Ishii H - J Diabetes Investig (2012)

 Duration of diabetes and HbA1c levels at baseline were significant determinants of the HbA1c level at 24 weeks. The HbA1c level to be attained at week 24 is calculated from the duration of diabetes and the HbA1c level at baseline.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4020734&req=5

f1:  Duration of diabetes and HbA1c levels at baseline were significant determinants of the HbA1c level at 24 weeks. The HbA1c level to be attained at week 24 is calculated from the duration of diabetes and the HbA1c level at baseline.
Mentions: Multiple linear regression analysis including HbA1c level at baseline, duration of diabetes, the number of classes of coadministered OADs, and HbA1c level at week 24 revealed that the duration of diabetes (β = 0.561; P < 0.001) and HbA1c level at baseline (β = 0.284; P = 0.006) were significant determinants of HbA1c level at 24 weeks (Figure 1). The best fitting multiple regression equation was: HbA1c level at week 24 = 0.078 × duration of diabetes + 0.218 × HbA1c level at baseline + 4.628 (r = 0.661; r2 = 0.437), on the conditions of diabetic duration in the range 1–35 years and HbA1c level in the range 7.5–14.5%.

Bottom Line: The aim of the present study was to determine which characteristics of patients could influence the effectiveness of BOT introduction, and to obtain an equation to estimate HbA1c after BOT initiation.   Sixty consecutive insulin-naive type 2 diabetic patients with poor glycemic control (HbA1c ≥7.5%) started once-daily injections of insulin glargine.The best fitting multiple regression equation was: HbA1c at week 24 = 0.078 × duration of diabetes + 0.218 × HbA1c at baseline + 4.628 (r (2) = 0.437).   The equation based on the multiple linear regression models indicates necessary conditions for type 2 diabetic patients to achieve target HbA1c.The present findings emphasize the principle that early initiation of BOT in type 2 diabetes effectively achieves good glycemic control. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00164.x, 2011).

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology, Tenri Hospital, Nara, Japan.

ABSTRACT

Unlabelled: Aims/Introduction:  A method of estimating HbA1c attained after initiation of basal supported oral therapy (BOT) has not been reported previously. The aim of the present study was to determine which characteristics of patients could influence the effectiveness of BOT introduction, and to obtain an equation to estimate HbA1c after BOT initiation.

Materials and methods:   Sixty consecutive insulin-naive type 2 diabetic patients with poor glycemic control (HbA1c ≥7.5%) started once-daily injections of insulin glargine. Simple correlations were calculated between parameters such as HbA1c at baseline, HbA1c at week 24, reduction rate of HbA1c over 24 weeks (calculated as: [HbA1c level at baseline - HbA1c level at week 24]/HbA1c level at baseline), duration of diabetes, and the number of classes of coadministered oral antidiabetic drugs. Using multiple linear regression models, the independent effects of these parameters on HbA1c at week 24 were evaluated separately.

Results:   Multiple linear regression analysis revealed that duration of diabetes (β = 0.561; P < 0.001) and HbA1c at baseline (β = 0.284; P = 0.006) were significant predictors of HbA1c at week 24. The best fitting multiple regression equation was: HbA1c at week 24 = 0.078 × duration of diabetes + 0.218 × HbA1c at baseline + 4.628 (r (2) = 0.437).

Conclusions:   The equation based on the multiple linear regression models indicates necessary conditions for type 2 diabetic patients to achieve target HbA1c. The present findings emphasize the principle that early initiation of BOT in type 2 diabetes effectively achieves good glycemic control. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00164.x, 2011).

No MeSH data available.


Related in: MedlinePlus